Evaluation of HLA-B*5701 screening prior to abacavir administration for prevention of the hypersensitivity reaction.

Evaluation of HLA-B*5701 screening prior to abacavir administration for prevention of the hypersensitivity reaction. - HLA-B*5701 screening for prevention of abacavir hypersensitivity reaction.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003095

Enrollment

Registered

2010-02-01

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection

Interventions

Abacavir is administered to HLA-B*5701-negative patients and the hypersensitivity will be judged in six weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HIV-infected patients, irrespective of antiretroviral treatment experience, considered to initiate a regimen containing abacavir.

Exclusion criteria

Exclusion criteria: Patients received abacavir once, or with severe hepatic dysfunction.

Design outcomes

Primary

Measure	Time frame
Proportion of abacavir-hypersensitive patients to the HLA-B*5701-negative.	—

Countries

Japan

Contacts

Public ContactToshiaki Igarashi

University of Fukui Hospital Department of Pharmacy

igarashi@u-fukui.ac.jp0776-61-3111(ext.3212)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026